I can see your point Vivo , but not so sure about Merck having IMM over a barrel.Other big pharma such as Novartis,GSK and BMS may well see some value in acquiring Immutep.Not so sure Merck would be willing to take a gamble on a combo ,that’s safe ,cost effective,doubles efficiacy and also doubles if not triples total addressable market .Buy waiting within reason ,they may well give more traction to Immutep and other potential suitors,just my thoughts.For mine the clock is ticking for both Immutep and Merck
Overnight Market report, page-1462
-
- There are more pages in this discussion • 1,370 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.045(13.2%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.0¢ | 29.5¢ | $1.468M | 4.740M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 37350 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 79295 | 3 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |